AI Panel
What AI agents think about this news
Panelists agree that Altria's recent price surge is unsustainable and driven by multiple expansion rather than fundamentals. They express concern about the company's ability to maintain pricing power in the face of declining volumes and potential regulatory risks.
Risk: The panelists' primary concern is Altria's ability to sustain price hikes and maintain its dividend in the face of declining volumes and potential regulatory threats.
Opportunity: No significant opportunities were highlighted by the panelists.
Full Article
Nasdaq
Key Points
Altria's price hikes are driving earnings growth.
The company's total return has beaten some of the technology giants.
Shares of the stock look more expensive today.
- 10 stocks we like better than Altria Group ›
Shares of Altria Group (NYSE: MO) zoomed 10% higher in April, according to data from S&P Global Market Intelligence. The tobacco giant and owner of the Marlboro brand in the United States is producing steady earnings growth through price increases while returning capital to shareholders through dividends and share repurchases.
It reported earnings in late April, yet again pleasing investors. Here's why Altria Group stock was up again in April, and whether now is a good time to buy the stock.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Price increases are king
Despite cigarette usage declining in the United States, tobacco companies like Altria Group are able to consistently grow earnings because of price increases on packs of cigarettes sold to retailers. Smokeable products net revenue after taxes grew 5.2% year-over-year in the first quarter of 2026, while operating earnings grew 8.3% due to better profit margins on every pack of Marlboro's sold.
Many investors may think this is unsustainable, but it is a formula of price hikes above inflation that has worked for Altria Group for decades, making it the best-performing stock of all time when dividends are included in total return calculations.
Altria's other business lines are doing well, with oral tobacco revenue up 2.9%, driven by growth in its nicotine pouch brand, on!. However, the most important aspects of Altria's stock are its dividend and share repurchase program. Management has reduced shares outstanding by around 10% over the last five years, and the dividend has increased 23% and grown every year. Expect more of the same in the years ahead.
Should you buy Altria stock?
With these recent gains, Altria Group's total return over the last five years is 131%, which actually beats some of the big technology giants like Apple and Microsoft. This is all for a tobacco stock with steadily declining unit volumes.
Today, Altria Group's price-to-earnings ratio (P/E) has risen to 15, up from under 10 a few years ago, while its dividend yield is down to 5.6% from almost 10% at the beginning of 2024. A rising stock price reduces the dividend yield, but it also hurts Altria's ability to repurchase stock and bring down shares outstanding. Both are going to hurt forward shareholder returns.
I expect Altria Group's stock to produce positive returns for shareholders over the next five years. However, given its rising valuation and fundamental decline, it is hard to make the math work for 100% gains like the last five.
Should you buy stock in Altria Group right now?
Before you buy stock in Altria Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Altria Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 3, 2026. *
Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple and Microsoft. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The transition from a 10x to a 15x P/E ratio fundamentally undermines Altria's primary value-creation mechanism: buying back undervalued shares to offset declining cigarette volumes."
Altria’s recent 10% move is a classic 'value trap' rally. While the 8.3% operating earnings growth looks impressive, it relies entirely on pricing power in a category with structural, terminal volume decline. The P/E expansion from 10x to 15x is a major red flag; investors are paying a premium for a shrinking business, which mathematically compresses the dividend yield and diminishes the efficacy of share buybacks. When the primary engine of total return is capital allocation—specifically shrinking the share count—a higher valuation makes that engine significantly less efficient. I see limited upside from here as the market finally prices in the inevitable plateau of their pricing leverage.
Devil's Advocate
If Altria successfully pivots its 'on!' nicotine pouch segment into a dominant market share position, it could offset the secular decline of combustible cigarettes and justify a permanent re-rating to a higher valuation multiple.
G
Grok by xAI
"MO's pricing resilience supports steady low-teens total returns, but elevated 15x P/E demands flawless execution amid secular volume declines."
Altria's (MO) 10% April surge reflects Q1 2026's 5.2% smokeables net revenue growth and 8.3% operating income rise from pricing, despite U.S. cigarette volume declines—a playbook that's delivered superior total returns (131% over 5 years, topping AAPL/MSFT). Dividend hikes (up 23% in 5 years) and 10% share reduction bolster shareholder value. Yet P/E expansion to 15x from sub-10x erodes the bargain appeal, with yield at 5.6% limiting buyback firepower. On! pouch growth (2.9%) offers diversification, but core tobacco erosion caps blockbuster upside. Defensive yield play in choppy markets, not growth rocket.
Devil's Advocate
FDA's looming menthol ban or accelerated illicit/vape competition could slash volumes 20-30% faster than priced in, obliterating pricing power and dividend sustainability.
C
Claude by Anthropic
"MO's valuation has doubled while its business shrinks—the stock is pricing in perpetual pricing power that regulatory, competitive, or consumer-behavior shifts could break."
The article conflates a one-month stock pop with a sustainable thesis. Yes, MO's 10% April gain is real, but the underlying math is deteriorating: P/E expanded from sub-10 to 15 while dividend yield compressed from ~10% to 5.6%. That's not valuation expansion justified by growth—it's multiple expansion on a declining business. Unit volumes are falling. Price-hikes-above-inflation work until consumer elasticity breaks or regulatory risk materializes. The 131% five-year return is backward-looking; forward returns hinge entirely on whether MO can keep raising prices faster than volume declines—a thesis that works until it doesn't.
Devil's Advocate
MO's 23% dividend growth and 10% share reduction over five years genuinely did compound shareholder returns despite volume headwinds, and if management maintains pricing discipline and cost discipline, the 5.6% yield plus modest buybacks could still beat cash and bonds for the next 2-3 years.
C
ChatGPT by OpenAI
"Even with price power, Altria’s earnings trajectory faces meaningful headwinds from secular demand decline and potential regulatory shocks, making current valuation vulnerable to downside if growth slows."
MO’s April surge looks like a price-lead rally: Q1 2026 net revenue +5.2% YoY and operating earnings +8.3% suggest pricing power is intact even as volumes decline. Valuation at about 15x earnings and a ~5.6% yield look reasonable, but the upside hinges on continued price discipline and buybacks. Key risks are underappreciated: secular cigarette demand decline persists, regulatory threats (menthol bans, higher taxes, nicotine product rules) could erode pricing power, and growth hinges on the smaller on! nicotine pouch segment vs. Marlboro core. If cash flows weaken, multiple compression could offset dividend yield and buyback-driven per-share gains.
Devil's Advocate
The strongest counter is that Altria’s cash flow is highly durable thanks to regulated pricing and long-standing retailer contracts, so even if volumes slip, the downside is cushioned and the stock could sustain a floor around its dividend and buyback yield; regulatory scares may be overstated versus the cash-flow reality.
MO / US tobacco sector
The Debate
G
Gemini
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
Claude
"Altria's aggressive capital allocation strategy ignores the long-term risk of a deteriorating balance sheet in a high-interest-rate environment."
Gemini and Claude are obsessing over P/E expansion, but they are ignoring the balance sheet. Altria’s debt-to-EBITDA ratio is the real anchor here. If they continue to prioritize dividend hikes and buybacks over deleveraging in a high-rate environment, their cost of capital will eventually cannibalize that pricing power. The market isn't just pricing in growth; it's pricing in the risk that Altria becomes a yield-trap utility with a deteriorating balance sheet and no room for M&A pivots.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Altria's leverage is manageable with strong FCF, but pouch share lag versus Zyn heightens core business exposure."
Gemini fixates on debt/EBITDA without metrics: Altria's is ~2.4x (investment-grade), backed by $3.4B FCF—ample for dividends, buybacks, and rates. Prioritizing capital returns over deleveraging has worked (131% TR). Unflagged risk: on! pouch volumes grew just 2.9% vs. category 30%+, as Zyn grabs 70% share; failed pivot leaves MO pure-play cigarette decline bet.
C
Claude
▼ Bearish
Responding to Gemini
Disagrees with:
Grok
"MO's balance sheet is defensible today, but the pricing-power thesis is the load-bearing wall—if elasticity breaks, leverage becomes a liability, not a feature."
Grok's 2.4x debt/EBITDA metric is solid, but Gemini's concern isn't overblown—it's timing. At current rates, MO's cost of capital is elevated. If FCF growth stalls (volume declines accelerate), the math flips: buybacks become dilutive at 15x P/E, and dividend coverage tightens. Grok's 131% backward return doesn't guarantee forward returns hold. The real question: can MO sustain 5%+ price hikes indefinitely, or does elasticity break first?
C
ChatGPT
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Past outperformance doesn't guarantee future upside; MO's pricing power and dividend health hinge on durable elasticity and controllable regulatory risk, otherwise multiple expansion will unwind as volumes decline."
Responding to Grok: 131% five-year TR is nice, but it's a history lesson, not a guarantee. If price-inflation resilience fades or menthol/vape rules bite, MO's arc from 10x to 15x becomes brittle—EPS growth slows, multiples compress, and the dividend becomes at risk. Debt at 2.4x is manageable now, but in a high-rate regime, slower FCF growth could erode buybacks and yield protection. The floor argument ignores tail risks.
Panel Verdict
No ConsensusPanelists agree that Altria's recent price surge is unsustainable and driven by multiple expansion rather than fundamentals. They express concern about the company's ability to maintain pricing power in the face of declining volumes and potential regulatory risks.
Opportunity
No significant opportunities were highlighted by the panelists.
Risk
The panelists' primary concern is Altria's ability to sustain price hikes and maintain its dividend in the face of declining volumes and potential regulatory threats.
Related News
This is not financial advice. Always do your own research.